Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis

医学 包涵体肌炎 内科学 肌炎 皮肤病科
作者
Anthony A. Amato,Michael G. Hanna,Pedro Machado,Umesh A. Badrising,Hector Chinoy,Olivier Benvéniste,Ananda Krishna Karanam,Min Wu,László B. Tankó,Agnes Annette Schubert-Tennigkeit,Dimitris A. Papanicolaou,Thomas E. Lloyd,Merrilee Needham,Christina Liang,Katrina Reardon,Marianne de Visser,Dana P. Ascherman,Richard J. Barohn,Mazen M. Dimachkie,James Miller
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:96 (12): e1595-e1607 被引量:37
标识
DOI:10.1212/wnl.0000000000011626
摘要

OBJECTIVE: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). METHODS: Participants (aged 36-85 years) who completed the core study (RESILIENT [Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients]) were invited to join an extension study. Individuals continued on the same treatment as in the core study (10 mg/kg, 3 mg/kg, 1 mg/kg bimagrumab or matching placebo administered as IV infusions every 4 weeks). The co-primary outcome measures were 6-minute walk distance (6MWD) and safety. RESULTS: Between November 2015 and February 2017, 211 participants entered double-blind placebo-controlled period of the extension study. Mean change in 6MWD from baseline was highly variable across treatment groups, but indicated progressive deterioration from weeks 24-104 in all treatment groups. Overall, 91.0% (n = 142) of participants in the pooled bimagrumab group and 89.1% (n = 49) in the placebo group had ≥1 treatment-emergent adverse event (AE). Falls were slightly higher in the bimagrumab 3 mg/kg group vs 10 mg/kg, 1 mg/kg, and placebo groups (69.2% [n = 36 of 52] vs 56.6% [n = 30 of 53], 58.8% [n = 30 of 51], and 61.8% [n = 34 of 55], respectively). The most frequently reported AEs in the pooled bimagrumab group were diarrhea 14.7% (n = 23), involuntary muscle contractions 9.6% (n = 15), and rash 5.1% (n = 8). Incidence of serious AEs was comparable between the pooled bimagrumab and the placebo group (18.6% [n = 29] vs 14.5% [n = 8], respectively). CONCLUSION: Extended treatment with bimagrumab up to 2 years produced a good safety profile and was well-tolerated, but did not provide clinical benefits in terms of improvement in mobility. The extension study was terminated early due to core study not meeting its primary endpoint. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02573467. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label design of extension treatment period 2.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
若梦完成签到,获得积分10
1秒前
哦哦完成签到 ,获得积分10
1秒前
共享精神的应助被cc采纳,获得10
2秒前
中级中级发布了新的文献求助10
3秒前
3秒前
高兴宝贝完成签到 ,获得积分10
3秒前
菲菲完成签到 ,获得积分10
3秒前
kepler完成签到,获得积分10
3秒前
科研通AI6.3的应助被whale采纳,获得10
4秒前
一一发布了新的文献求助10
5秒前
甜蜜发带完成签到 ,获得积分10
5秒前
5秒前
5秒前
科研通AI6.4的应助被12采纳,获得30
6秒前
6秒前
111完成签到,获得积分10
6秒前
完美凛完成签到 ,获得积分10
6秒前
xie完成签到 ,获得积分20
7秒前
小芳儿发布了新的文献求助10
8秒前
helicopter完成签到 ,获得积分10
8秒前
小台完成签到,获得积分10
8秒前
9秒前
汉堡包的应助被中级中级采纳,获得10
9秒前
匿名用户完成签到,获得积分10
10秒前
天天快乐的应助被ylhx1102采纳,获得10
10秒前
小卷发布了新的文献求助10
11秒前
Edgar完成签到,获得积分0
11秒前
hi完成签到,获得积分10
12秒前
12秒前
11发布了新的文献求助10
13秒前
阮宁完成签到 ,获得积分10
13秒前
yyjlo发布了新的文献求助10
14秒前
Nora完成签到,获得积分10
14秒前
zhangjoy完成签到,获得积分10
14秒前
秦桂敏完成签到 ,获得积分10
15秒前
daomaihu发布了新的文献求助100
15秒前
15秒前
szh123完成签到,获得积分10
15秒前
15秒前
Garlicdog完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175336
求助须知:如何正确求助?哪些是违规求助? 9567158
关于积分的说明 21790491
捐赠科研通 7769866
什么是DOI,文献DOI怎么找? 3431849
关于科研通互助平台的介绍 2556178
邀请新用户注册赠送积分活动 2477280